SEC Form 4 · accession 0001776977-26-000010
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Julie Cooke
Officer — Chief Human Resources Officer
Period of report
Jun 2, 2026
Accepted (ET)
Jun 4, 2026 · 6:02 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 2, 2026 | M | 24,965 | $81.49 | A | 59,311 | D | |
| Common StockF3 | Jun 2, 2026 | S | 14,214 | $154.8252 | D | 45,097 | D | |
| Common StockF4 | Jun 2, 2026 | S | 5,466 | $155.4566 | D | 39,631 | D | |
| Common StockF5 | Jun 2, 2026 | S | 4,216 | $156.766 | D | 35,415 | D | |
| Common StockF6 | Jun 2, 2026 | S | 9,521 | $157.6161 | D | 25,894 | D | |
| Common StockF7,F8 | Jun 2, 2026 | S | 3,520 | $158.5897 | D | 22,374 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF9 | $81.49 | Jun 2, 2026 | M | 24,965 | D | — | Feb 5, 2028 | Common Stock | 24,965 | 0 | D |
Explanation of responses
- F1Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
- F2The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F3Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $154.20 to $155.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.20 to $156.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $156.26 to $157.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.26 to $158.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $158.26 to $158.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F820,334 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.
- F9The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.